C
CRISPR Therapeutics
Gene-based medicines for patients with serious diseases
At a glance
- Status
- Listed
- Listing
- IPO 2016
Open roles
CRISPR Therapeutics in its local ecosystem
The CRISPR Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later14 investors entered at this stage
- SOSR One
- CPClough Capital Partners
- GSGSK
- NPNew Leaf Venture Partners
Vertex Holdings
NEA- BSBristol-Myers Squibb
- CECelgene
Wellington Management- BIBayer Global Investments
- ABAbingworth
Franklin Templeton Investments
Vivo Capital- VPVertex Pharmaceuticals
Source: Dealroom Talent Intelligence.
Alumni founders
Former CRISPR Therapeutics employees who went on to found companies, sorted by Dealroom signal score.
ZBZag BioEst. 2022
CTClade TherapeuticsEst. 2020
Chad CowanUnited States
VBVernal BiosciencesEst. 2021
Christian CobaughUnited States
ATAirNexis TherapeuticsEst. 2025
Maria FardisUnited StatesPatents
109 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See CRISPR Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Marrow debuts with $120M Series B to target blood disorders in vivo
Seawolf exits stealth with $100M for DNA-based therapies
ARK pours $17M into Cerebras, exits AMD and Palantir
